Search Results for "Odac Marqibo 2012"

00:28 EST 21st December 2014 | BioPortfolio

Matching Channels


Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...


Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...


Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...


Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...

Matching News

Big biotech, Spectrum Pharma and CASI Pharma signed a licensing agreement

China-based, CASI has signed a licensing agreement with big biotech, Spectrum Pharma’s for its products: Zevalin, Marqibo and Melphalan. CASI has been granted exclusive rights to two of Spectrum...

Applying Avastin's lessons

ODAC rebuffed early approval of AZ's olaparib for ovarian cancer to avoid an Avastin-like scenario, where initial PFS didn't bear out.

Panobinostat push back

ODAC thinks Novartis should study different combinations or doses of panobinostat to reduce side effects in multiple myeloma.

FDA delays verdict for Novartis' panobinostat

The ODAC said the 3.9 months median improvement in progression-free survival was not enough to recommend approval of panobinostat in multiple myeloma.

Increased deaths may hang up Novartis' panobinostat at ODAC

Regulators also noted patients experienced several adverse events with the drug, including myelosuppression, hemorrhage, infection and gastrointestinal and cardiac toxicity.

Rock-Solid Triferic Heads Toward ODAC Review

Rockwell Medical Inc.’s ferric pyrophosphate seems poised to help firm’s emerging dialysis franchise if FDA is comfortable with an imbalance of deaths deemed not related to the drug seen in pivota...

FDA panel: AstraZeneca olaparib not ready to fly solo

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 11-2 the safety and efficacy results of AstraZeneca's single trial, known as study 19, in patients with germline BRCA mutation (gBRCAm) ovaria...

FDA questions validity/reproducibility of AstraZeneca's olaparib efficacy data

In briefing documents released ahead of a 25 June meeting of the agency's Oncologic Drugs Advisory Committee (ODAC), regulators also raised concerns about the risks associated with olaparib therapy, s...

Matching PubMed Articles

Influenza in Poland in 2011-2012 and in 2011/2012 and 2012/2013 epidemic seasons.

This paper aimed at evaluating the epidemiological situation of influenza in Poland in 2011-2012 and in 2011/2012 and 2012/2013 epidemic seasons and comparing it with the situation observed in the pre...

Proceedings of the 2012 Sino-European Symposium on Environment and Health (SESEH 2012), August 20-25, 2012, Galgay, Ireland.

Introduction to the special issue for ISAF-ECAPD-PFM 2012.

This special issue contains some of the papers presented at the joint ISAF-ECAPD-PFM 2012 meeting, combining the 21st IEEE International Symposium on Applications of Ferroelectrics (ISAF 2012), the 11...

Treasurer's Report, 2012 Statement of Activities For the year ending December 31, 2012.

Burden of influenza B virus infections in Scotland in 2012/13 and epidemiological investigations between 2000 and 2012.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement